Capricor Therapeutics, Inc. (CAPR) Stock Analysis

Company Overview

Capricor Therapeutics, Inc. (CAPR) is capitalised at $400.00M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 231 employees.

CAPR last closed at $5.88 on October 21, 2026. That is −$0.73 (−11.04%) against the previous close. The 52-week range on file runs from $2.96 to $40.37. The latest close sits 98.65% above that 52-week low.

Financial Health

In fiscal 2025, Capricor Therapeutics, Inc. reported revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $22.27M. The same year closed with a net loss of $105.04M. Earnings per share on a trailing basis come to −2.45.

Across the 4 fiscal years on file, revenue moves from $2.55M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.38.

Over the trailing twelve months the total return is −7.69%. Measured over 10 years, that is −15.64% a year compounded. The reported beta is 0.61. Annualized volatility over the trailing 10 years is 182.79%.

Growth & Income

The record shows no dividend for CAPR.

2026 is still running; the total return is −79.63% year to date. Across the complete calendar years on file, 2024 returned +182.21% and 2018 returned −74.05%. Of the 9 complete calendar years on file, 5 finished higher.